These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 16965988)

  • 1. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy.
    Jolly S; Kestin LL; Goldstein NS; Vicini FA
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):365-71. PubMed ID: 16965988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving local control with breast-conserving therapy: a 27-year single-institution experience.
    Cabioglu N; Hunt KK; Buchholz TA; Mirza N; Singletary SE; Kuerer HM; Babiera GV; Ames FC; Sahin AA; Meric-Bernstam F
    Cancer; 2005 Jul; 104(1):20-9. PubMed ID: 15912514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.
    Fisher ER; Costantino J; Fisher B; Palekar AS; Paik SM; Suarez CM; Wolmark N
    Cancer; 1996 Oct; 78(7):1403-16. PubMed ID: 8839545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predicting in-breast tumor recurrence after breast-conserving surgery.
    Mechera R; Viehl CT; Oertli D
    Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal use of re-excision in patients diagnosed with early-stage breast cancer by excisional biopsy treated with breast-conserving therapy.
    Caughran JL; Vicini FA; Kestin LL; Dekhne NS; Benitez PR; Goldstein NS
    Ann Surg Oncol; 2009 Nov; 16(11):3020-7. PubMed ID: 19636632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast conservation therapy for invasive lobular carcinoma: the impact of lobular carcinoma in situ in the surgical specimen on local recurrence and axillary node status.
    Stolier AJ; Barre G; Bolton JS; Fuhrman GM; Looney S
    Am Surg; 2004 Sep; 70(9):818-21. PubMed ID: 15481302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ.
    Fisher ER; Land SR; Fisher B; Mamounas E; Gilarski L; Wolmark N
    Cancer; 2004 Jan; 100(2):238-44. PubMed ID: 14716756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma.
    Leong C; Boyages J; Jayasinghe UW; Bilous M; Ung O; Chua B; Salisbury E; Wong AY
    Cancer; 2004 May; 100(9):1823-32. PubMed ID: 15112262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Rudloff U; Brogi E; Brockway JP; Goldberg JI; Cranor M; Wynveen CA; Nehhozina T; Reiner AS; Patil S; Van Zee KJ
    Cancer; 2009 Mar; 115(6):1203-14. PubMed ID: 19170233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases.
    Komoike Y; Akiyama F; Iino Y; Ikeda T; Akashi-Tanaka S; Ohsumi S; Kusama M; Sano M; Shin E; Suemasu K; Sonoo H; Taguchi T; Nishi T; Nishimura R; Haga S; Mise K; Kinoshita T; Murakami S; Yoshimoto M; Tsukuma H; Inaji H
    Cancer; 2006 Jan; 106(1):35-41. PubMed ID: 16333848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience.
    Sahoo S; Recant WM; Jaskowiak N; Tong L; Heimann R
    Breast J; 2005; 11(4):242-7. PubMed ID: 15982389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is lobular carcinoma in situ as a component of breast carcinoma a risk factor for local failure after breast-conserving therapy? Results of a matched pair analysis.
    Ben-David MA; Kleer CG; Paramagul C; Griffith KA; Pierce LJ
    Cancer; 2006 Jan; 106(1):28-34. PubMed ID: 16329136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of local failure in breast cancer patients with lobular carcinoma in situ at the final surgical margins: is re-excision necessary?
    Sadek BT; Shenouda MN; Abi Raad RF; Niemierko A; Keruakous AR; Goldberg SI; Taghian AG
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):726-30. PubMed ID: 24064317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
    Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
    Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery.
    Cabioglu N; Hunt KK; Sahin AA; Kuerer HM; Babiera GV; Singletary SE; Whitman GJ; Ross MI; Ames FC; Feig BW; Buchholz TA; Meric-Bernstam F
    Ann Surg Oncol; 2007 Apr; 14(4):1458-71. PubMed ID: 17260108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in temporal patterns of local failure after breast-conserving therapy and their prognostic implications.
    Krauss DJ; Kestin LL; Mitchell C; Martinez AA; Vicini FA
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):731-40. PubMed ID: 15465189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences.
    Huang E; Buchholz TA; Meric F; Krishnamurthy S; Mirza NQ; Ames FC; Feig BW; Kuerer HM; Ross MI; Singletary SE; McNeese MD; Strom EA; Hunt KK
    Cancer; 2002 Nov; 95(10):2059-67. PubMed ID: 12412158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Breast-conserving treatment for early invasive lobular breast cancer: 15 years results].
    Fodor J; Sulyok Z; Polgár C; Major T; Tóth J; Németh G
    Magy Seb; 2001 Aug; 54(4):209-14. PubMed ID: 11550486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.